LRMR
Price
$3.44
Change
-$0.02 (-0.58%)
Updated
Aug 1 closing price
Capitalization
219.94M
5 days until earnings call
OCUL
Price
$11.92
Change
+$0.34 (+2.94%)
Updated
Aug 1 closing price
Capitalization
1.9B
2 days until earnings call
Interact to see
Advertisement

LRMR vs OCUL

Header iconLRMR vs OCUL Comparison
Open Charts LRMR vs OCULBanner chart's image
Larimar Therapeutics
Price$3.44
Change-$0.02 (-0.58%)
Volume$1.16M
Capitalization219.94M
Ocular Therapeutix
Price$11.92
Change+$0.34 (+2.94%)
Volume$1.65M
Capitalization1.9B
LRMR vs OCUL Comparison Chart in %
Loading...
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LRMR vs. OCUL commentary
Aug 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LRMR is a Hold and OCUL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 03, 2025
Stock price -- (LRMR: $3.44 vs. OCUL: $11.92)
Brand notoriety: LRMR and OCUL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LRMR: 98% vs. OCUL: 68%
Market capitalization -- LRMR: $219.94M vs. OCUL: $1.9B
LRMR [@Biotechnology] is valued at $219.94M. OCUL’s [@Biotechnology] market capitalization is $1.9B. The market cap for tickers in the [@Biotechnology] industry ranges from $213.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LRMR’s FA Score shows that 1 FA rating(s) are green whileOCUL’s FA Score has 0 green FA rating(s).

  • LRMR’s FA Score: 1 green, 4 red.
  • OCUL’s FA Score: 0 green, 5 red.
According to our system of comparison, both LRMR and OCUL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LRMR’s TA Score shows that 3 TA indicator(s) are bullish while OCUL’s TA Score has 3 bullish TA indicator(s).

  • LRMR’s TA Score: 3 bullish, 5 bearish.
  • OCUL’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both LRMR and OCUL are a bad buy in the short-term.

Price Growth

LRMR (@Biotechnology) experienced а -11.34% price change this week, while OCUL (@Biotechnology) price change was -2.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.14%. For the same industry, the average monthly price growth was +15.55%, and the average quarterly price growth was +36.18%.

Reported Earning Dates

LRMR is expected to report earnings on Nov 18, 2025.

OCUL is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+0.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OCUL($1.9B) has a higher market cap than LRMR($220M). OCUL YTD gains are higher at: 39.578 vs. LRMR (-11.111). LRMR has higher annual earnings (EBITDA): -105.02M vs. OCUL (-176.35M). OCUL has more cash in the bank: 350M vs. LRMR (158M). LRMR has less debt than OCUL: LRMR (4.87M) vs OCUL (76.2M). OCUL has higher revenues than LRMR: OCUL (59.6M) vs LRMR (0).
LRMROCULLRMR / OCUL
Capitalization220M1.9B12%
EBITDA-105.02M-176.35M60%
Gain YTD-11.11139.578-28%
P/E RatioN/AN/A-
Revenue059.6M-
Total Cash158M350M45%
Total Debt4.87M76.2M6%
FUNDAMENTALS RATINGS
LRMR vs OCUL: Fundamental Ratings
LRMR
OCUL
OUTLOOK RATING
1..100
8381
VALUATION
overvalued / fair valued / undervalued
1..100
23
Undervalued
57
Fair valued
PROFIT vs RISK RATING
1..100
10080
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
5238
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LRMR's Valuation (23) in the null industry is somewhat better than the same rating for OCUL (57) in the Pharmaceuticals Other industry. This means that LRMR’s stock grew somewhat faster than OCUL’s over the last 12 months.

OCUL's Profit vs Risk Rating (80) in the Pharmaceuticals Other industry is in the same range as LRMR (100) in the null industry. This means that OCUL’s stock grew similarly to LRMR’s over the last 12 months.

OCUL's SMR Rating (96) in the Pharmaceuticals Other industry is in the same range as LRMR (100) in the null industry. This means that OCUL’s stock grew similarly to LRMR’s over the last 12 months.

OCUL's Price Growth Rating (38) in the Pharmaceuticals Other industry is in the same range as LRMR (52) in the null industry. This means that OCUL’s stock grew similarly to LRMR’s over the last 12 months.

OCUL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as LRMR (100) in the null industry. This means that OCUL’s stock grew similarly to LRMR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LRMROCUL
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
86%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 11 days ago
86%
Bullish Trend 11 days ago
80%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
81%
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BGCSX15.25-0.07
-0.46%
Baillie Gifford EAFE Plus All Cap I
FPCSX42.97-0.45
-1.04%
FPA Crescent Supra Institutional
IGLGX20.35-0.24
-1.17%
Columbia Select Global Equity A
MCDCX20.28-0.27
-1.31%
BlackRock Emerging Mkts Inv C
PZVSX12.39-0.36
-2.82%
Pzena Small Cap Value Investor

LRMR and

Correlation & Price change

A.I.dvisor indicates that over the last year, LRMR has been loosely correlated with ERAS. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if LRMR jumps, then ERAS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LRMR
1D Price
Change %
LRMR100%
-0.58%
ERAS - LRMR
52%
Loosely correlated
-1.77%
SYRE - LRMR
50%
Loosely correlated
-4.18%
ALEC - LRMR
49%
Loosely correlated
-2.68%
ACLX - LRMR
48%
Loosely correlated
-0.35%
OCUL - LRMR
48%
Loosely correlated
+2.94%
More